Quantcast

Bionovo, Inc. to Announce Fourth Quarter and Year-End Financial Results on Thursday, March 12, 2009

March 6, 2009

Company to Review Plans for 2009

EMERYVILLE, Calif., March 6 /PRNewswire-FirstCall/ — Bionovo, Inc. (Nasdaq: BNVI) announced today that it will release financial results for the fourth quarter and the year ended December 31, 2008 on Thursday, March 12, 2009. The Company will conduct a conference call and web cast to review the financial results and the Company’s plans for 2009 on Thursday, March 12, 2009 at 4:30 p.m. ET.

Interested parties can access the call by dialing (877) 356-5706 or (706) 643-0580, or can listen via a live Internet web cast, which can be found at http://bionovo.com/investors/events. A replay of the call is available via web cast at http://bionovo.com/investors/events for 30 days or by playback at (800) 642-1687 or (706) 645-9291, access code 88102099, through March 15, 2009.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women’s health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, “BNVI”. For more information about Bionovo and its programs, visit: http://www.bionovo.com. BNVI-F

    Contacts:
         Bionovo, Inc.                     Lytham Partners, LLC
         Claire Fong                       Joe Diaz, Robert Blum, Joe Dorame
         Tom Chesterman                    (602) 889-9700
         (510) 601-2000                    BNVI@lythampartners.com
         investor@bionovo.com

SOURCE Bionovo, Inc.


Source: newswire



comments powered by Disqus